Iris Zemzoum President, Novartis Asia Pacific, Middle East & Africa (APMA)
- Sep 22, 2022
- 1 min read
Updated: Aug 26, 2024

22 September 2022
In an interview with PharmaBoardroom, Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis' multipronged approach to overcoming healthcare disparities across a diverse region that is home to half the world's population.
Read the article here.